Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
AT278 delivers significantly accelerated PK/PD profile compared to NovoRapid®
Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices
Potential to enable more effective disease management for insulin resistant patients requiring >200 units of insulin per day
Cambridge, UK, 20…
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member.
Mr. Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently chief executive officer and a director of Strongbridge…
IBX, a global leader in biobanking, bioprocessing and analytics, has acquired UK based biospecimen storage specialists Roylance Pharma
“The team and capabilities within Roylance Pharma perfectly complement those within IBX. Establishing a solid biobanking and bioprocessing hub in the UK servicing Europe, reinforces not only the IBX strategy and mission but also our proposition to clients and commitment to providing world leading biomaterial services,” said Grimwood.
Benedict Roylance, Co-Founder of Roylance Pharma, said “Joining Roylance Pharma and IBX is a natural fit that will benefit both…
CY Partners are delighted to announce the opening of their new office in London over the summer. It comes on the back of several years’ growth within the southern region for this niche science recruitment firm originating from Newcastle. In the London office currently works the wonderful Neil Walton and Matt Williams with support in payroll, marketing and key account servicing coming from the wider CY Partners team. They are looking to expand imminently so get in touch if you’re interested in joining them! They have worked incredibly hard and have seen much success both before and after…
AMSBIO has launched STEM-CELLBANKER® EX - a next generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.Rapid developments in cell, tissue, and gene therapies over the last decade have redefined what a cell therapy can be. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. However, the development of a cell therapy using a process that includes the washing out of the…
Cambridge and London, UK: 14 September 2021
One Nucleus, the non-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. Supporting companies throughout their life cycle. This includes facilitating connections between entrepreneurs and company-makers, including investors. Deep Science Ventures (DSV) operate across multiple sectors combining world-leading knowledge, talent and investment to form high impact new…
Leading pharmaceutical and biotech product development consultancy Boyds has announced the opening of its US office in the Philadelphia area and welcomes Katy Rudnick who is appointed Vice President and Head of US Regulatory Affairs to head up the newly established US company.
Since Boyds was established in 2005, the company has worked with US companies seeking to develop and gain approval for their medicines in Europe and further afield. Boyds’ global reputation for its work in advanced therapies has led to a steady increase in the number of companies approaching Boyds for this expertise,…
Cambridge, UK, 9 September 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes.The IND supports a Phase I clinical trial in the US in approximately 24 participants with type I diabetes, to further explore the clinical benefits of AT247. The trial is a double blind, randomised, three…
In this trial of preliminary issues, Zacaroli J held that when assessing the damages payable to multiple claimants under cross-undertakings given in respect of various interim injunctions and orders (and for unjustified threats of patent infringement), a single set of counterfactual assumptions should apply to all inquiry claimants, where those claimants operate in the same, largely finite, market. The decision is the latest in a long line of judgments concerning Pfizer’s pregabalin product, Lyrica®.
Pfizer held the marketing authorisation for pregabalin (branded Lyrica®) and Warner-Lambert (…
Cambridge, UK, 07 September 2021– Arecor Therapeutics plc, the biopharmaceutical group which is advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd (“Intas”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated product for Intas. The new product formulation supports improved usability for the patient compared to current marketed products and in particular facilitates home use outside of a healthcare environment. Intas will…